Celularity Inc. Form 8-K Summary
Business context and reporting period
Celularity Inc. filed a Form 8-K dated May 16, 2023, with the report signed and filed on May 19, 2023. The filing reports a private placement of equity securities and the resignation of Bradley Glover, Ph.D., Executive Vice President and Chief Operating Officer.
Financing and key financial terms
- Celularity sold 5,813,945 shares of Class A common stock at $0.52 per share and accompanying warrants to purchase 5,813,945 additional shares at $0.125 per warrant.
- The aggregate purchase price was approximately $3.75 million. The closing occurred on May 18, 2023.
- Each PIPE Warrant has an exercise price of $1.00 per share, is immediately exercisable, and expires on May 18, 2028.
- The warrants include customary capitalization adjustments and beneficial-ownership exercise limitations.
- Net proceeds are intended for working capital and general corporate purposes. The filing does not provide a clear value for net proceeds after transaction expenses.
- The securities were issued in an unregistered private placement under Section 4(a)(2) of the Securities Act and Regulation D.
Material changes and management
- The financing increases shares outstanding by 5,813,945 shares, before any warrant exercises, and creates potential dilution from up to 5,813,945 additional shares underlying the warrants.
- Bradley Glover notified Celularity on May 16, 2023, that he would resign as Executive Vice President and Chief Operating Officer effective May 31, 2023, to pursue another opportunity.
- The company stated that Mr. Glover’s resignation was not related to any disagreement with Celularity concerning its operations, policies, or practices.
Registration, outlook, and risks
- Celularity entered into a registration rights agreement covering resale of the purchased shares and shares issuable upon warrant exercise.
- The company agreed to file a resale registration statement within 30 days after closing and to use commercially reasonable efforts to obtain effectiveness within 45 days if the SEC does not review it, or within 90 days if the SEC reviews it, and no later than July 31, 2023.
- The securities were not registered under the Securities Act or state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption.
- The filing provides no additional revenue, profit, cash-flow, margin, debt, liquidity, operating guidance, or broader financial outlook information.
Investor verification points
- Verify the final number of shares issued, warrant terms, exercise limitations, and any subsequent warrant exercises or share issuance.
- Review the securities purchase agreement, PIPE Warrant, and registration rights agreement filed as Exhibits 10.1, 10.2, and 10.3.
- Confirm whether the resale registration statement was filed and became effective by the stated deadlines.
- Assess the effect of the financing and potential warrant dilution on existing shareholders.
- Monitor the impact of the Chief Operating Officer’s departure and any announced successor or revised operating responsibilities.